Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Lymphoma 58Multiple Myeloma 52Leukemia 48Leukemia, Myeloid, Acute 44Precursor Cell Lymphoblastic Leukemia-Lymphoma 41Myelodysplastic Syndromes 37Lymphoma, Non-Hodgkin 37Hodgkin Disease 36Lymphoma, Mantle-Cell 26Lymphoma, Large B-Cell, Diffuse 26Leukemia, Lymphocytic, Chronic, B-Cell 25Lymphoma, Follicular 22Breast Neoplasms 22Burkitt Lymphoma 21Lymphoma, B-Cell, Marginal Zone 16Congenital Abnormalities 15Lymphoma, Large-Cell, Immunoblastic 14Recurrence 13Leukemia, Myelogenous, Chronic, BCR-ABL Positive 13Sarcoma 12Neoplasms, Plasma Cell 12Hematologic Neoplasms 10Leukemia, Myelomonocytic, Juvenile 9Leukemia, Biphenotypic, Acute 9Blast Crisis 9Neoplasms 8Myeloproliferative Disorders 8Leukemia, Myelomonocytic, Chronic 8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 7Neuroblastoma 7

Interventions

Temozolomide 53Bevacizumab 33Radiotherapy 27Radiation 12Erlotinib Hydrochloride 12Radiotherapy, Intensity-Modulated 8Radiotherapy, Conformal 8Irinotecan 6Vorinostat 5Sorafenib 5Sirolimus 5temsirolimus 4Magnetic Resonance Spectroscopy 4Immunoglobulin G 4Disulfides 4Carmustine 4veliparib 3plerixafor 3carmustine, poliferprosan 20 drug combination 3Radiosurgery 3Everolimus 3Dasatinib 3Bortezomib 3vandetanib 2tandutinib 2sargramostim 2poly ICLC 2pembrolizumab 2pazopanib 2ferric pyrophosphate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Gliosarcoma × Filgrastim × Clear all
NCT00669669 2022-05-18

O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas

Fred Hutchinson Cancer Center

Phase 1/2 Terminated
12 enrolled 13 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡